Calcium Channel Blocker Drugs Market to Surpass US$ 21,489.7 Mn by 2030
The Global Calcium Channel Blocker Drugs Market, by Drug Class (Benzothizepine, Dihydropyridine and Phenylalkylamine), by Disease Indication (Hypertension, Chest Pain, Arrhythmias, and Others (Blood vessel conditions, Coronary Artery Disease etc.)), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 14,285.3 million in 2022 and expected to exhibit a CAGR of 5.2% over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing prevalence of chronic kidney disease is expected to drive growth of the calcium channel blocker drugs market. For instance, according to the Centers for Disease Control and Prevention (CDC), 15% of adults in the U.S., which is around 37 million people, were estimated to have chronic kidney disease in 2019.
Furthermore, adoption of inorganic growth strategies by major companies operating in this market such as collaborations, agreements, partnerships, and acquisitions to strengthen their market share is further fuelling growth of the calcium channel blocker drugs market
For instance, in 2021, Milestone Pharmaceuticals Inc., a biopharmaceutical company entered into an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals (Ji Xing) to develop and commercialize etripamil for PSVT in Greater China.
Etripamil is a novel calcium channel blocker designed to be a rapid-response therapy for episodic cardiovascular conditions.
Global Calcium Channel Blocker Drugs Market – COVID-19 Impact (Economic Impact)
The COVID-19 pandemic has negatively impacted the global economy and in turn, the calcium channel blocker drugs market. Quarantine, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending until the end of the second quarter of 2020. Moreover, the COVID-19 pandemic has drastically affected clinical trials. Many trials have paused enrollment and researchers are facing multiple challenges associated with setting up remote visits, and performing laboratory, and other study assessments.
Browse 29 Market Data Tables and 32 Figures spread through 185 Pages and in-depth TOC on “Calcium Channel Blocker Drugs Market”- Global Forecast to 2022, by Drug Class (Benzothizepine, Dihydropyridine and Phenylalkylamine), by Disease Indication (Hypertension, Chest Pain, Arrhythmias, and Others (Blood vessel conditions, Coronary Artery Disease etc.)), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Global Calcium Channel Blocker Drugs Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/calcium-channel-blocker-drugs-market-5153
Key Takeaways of the Global Calcium Channel Blocker Drugs Market:
- The global calcium channel blocker drugs market is expected to exhibit a CAGR of 5.2% over the forecast period, owing to increasing prevalence of angina pectoris. For instance, according to the article published in Medscape Journal in 2018, Angina pectoris is a common presenting symptom (typically, chest pain) among patients with coronary artery disease (CAD), around 9.8 million people in America experience angina pectoris annually with occurring of 500,000 new cases of angina every year.
- Among Drug Class, the Dihydropyridine segment is expected to account for the largest market share in 2021, dihydropyridine which target the calcium channels located in the muscle cells of the heart and arterial blood vessels, thereby reducing the entry of calcium ions into the cell.
- Key players operating in the global calcium channel blocker drugs market include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc.
Contact Us